Let's look at why this news could be a game-changer for Eli Lilly and its stock.

Once-daily orforglipron was more effective than placebo and just as safe as injectable GLP-1s in patients with diabetes and ...

Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. | Eli Lilly has met its goal of ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight ... So, Eli Lilly appears to have solid liquidity for the next twelve months. Long-term debt was $28.644 ...

Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small-molecule GLP-1 that is administered ... highest dose of the drug scored an A1C less ...

Eli Lilly’s shares shot up 11% pre-market on Thursday after orforglipron became the first small-molecule GLP-1 drug to ace a ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity ... a competitive efficacy and tolerability profile in Phase 3 testing.” The company added that the overall ...

Orforglipron reported its first phase 3 results from the Achieve ... orforglipron's potential as the leading oral GLP-1 candidate, a class of drugs with massive market potential if ultimately ...

Research published this week has found that GLP-1 drugs are associated with a lower ... have launched two large-scale phase III trials testing semaglutide for people with early Alzheimer’s ...